|
Invited speakers |
 |
|
Opening lecture
|
|
|
University of Geneva, Switzerland
|
Nature, an almost untapped reservoir of new drugs |
|
Plenary lectures
|
|
|
Torrey Pines Institute, USA
|
The direct in vivo screening of mixture-based combinatorial libraries for the identification of novel analgesics
|
|
|
Swiss Institute of Bioinformatics, Switzerland
|
The CALIPHO project: bioinformatics and laboratory approaches targeted towards human proteins. Some thoughts relevant to peptides |
|
|
Kai Pharmaceuticals, USA
|
Intracellular targeting of select protein kinase C isozymes with rationally designed peptides; from the bench to the clinic
|
|
|
Novo Nordisk, Denmark |
Ligand-bound structures of the GLP-1 receptor extracellular domain
|
|
|
Xigen Pharma, Switzerland |
Clinical development of XG-102, a cell penetrating kinase inhibitor peptide |
|
|
Pamet AG, Germany |
Noninvasive and targeted transcutaneous delivery of drugs, including peptides
|
|
|
MannKind Corporation, USA |
Early development of GLP-1 Technosphere® powder for inhalation
|
|
|
TransMolecular Inc, USA |
TM601's present and future applications in the clinic
|
|
Closing lecture
|
|
|
Tufts University and Peptide Therapeutics Foundation, USA |
Peptides to drugs pipeline |
|
Round Table:
Evaluation licensing and strategic alliances: how to be successful?
|
|
|
Partner, Aveo Partners, Switzerland |
Key issues in strategic alliances and parterning and mechanics in making strategic alliances |
|
|
CEO, Debiopharm, Switzerland |
The evaluation of a molecule by a drug development company: some critical aspects
|
|
|
Vice President, New Technology Development,Genzyme Pharmaceuticals, USA |
The rise of biotechnology, is larger better? |
|
|
|
Last Update:
08-04-2010 14:51
|
|
